Literature DB >> 9541335

Substance abuse in schizophrenia: a review.

P F Buckley1.   

Abstract

Approximately half of the patients who suffer from schizophrenia are also substance abusers at some time during their illness. The motivational drive toward abusive consumption is compounded in individuals with schizophrenia who turn toward substances with reinforcing properties to alleviate aspects of psychosis. This review examines the prevalence, etiology, and clinical effects of substance abuse (e.g., alcohol, nicotine, cocaine) among individuals with schizophrenia. Clearly, substance abuse persists despite and in spite of treatment with typical antipsychotics. The efficacy of newer generation antipsychotics in the reduction of substance abuse among the schizophrenic population has yet to be established, but clozapine has been shown to reduce alcohol, smoking, and cocaine use. Hence, clozapine is a therapeutic option for dually diagnosed patients because of its superior efficacy relative to conventional neuroleptics and its capacity to control substance abuse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541335

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  32 in total

1.  Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia.

Authors:  R Andrew Chambers; David W Self
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

2.  Auditory steady state response in bipolar disorder: relation to clinical state, cognitive performance, medication status, and substance disorders.

Authors:  Olga Rass; Giri Krishnan; Colleen A Brenner; William P Hetrick; Colleen C Merrill; Anantha Shekhar; Brian F O'Donnell
Journal:  Bipolar Disord       Date:  2010-12       Impact factor: 6.744

Review 3.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 4.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

Review 5.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 6.  Neurologic manifestations of chronic methamphetamine abuse.

Authors:  Daniel E Rusyniak
Journal:  Neurol Clin       Date:  2011-06-24       Impact factor: 3.806

Review 7.  Postpsychotic depression in schizophrenia patients.

Authors:  Christian G Kohler; Elise A Lallart
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

8.  Demographic and clinical correlates of substance abuse comorbidity in schizophrenia.

Authors:  Tapas K Aich; Vinod K Sinha; Christoday R J Khess; Shailja Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

9.  GABAergic modulation of the 40 Hz auditory steady-state response in a rat model of schizophrenia.

Authors:  Jenifer L Vohs; R Andrew Chambers; Giri P Krishnan; Brian F O'Donnell; Sarah Berg; Sandra L Morzorati
Journal:  Int J Neuropsychopharmacol       Date:  2009-07-23       Impact factor: 5.176

10.  Novel research translates to clinical cases of schizophrenic and cocaine psychosis.

Authors:  João V Nunes; Patricia A Broderick
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.